HIMSS and AVIA Launch HX360™ to Improve Health Care Delivery through Emerging Technologies

CHICAGO, Oct. 8, 2014-- Today, Healthcare Information and Management Systems Society (HIMSS) and AVIA announced HX360™, a new co-developed initiative. HX360 was created to improve the way that health care is delivered by both inspiring and facilitating the adoption and use of next generation (non-EHR Platform) technologies by provider organizations, in areas where health system executives are passionate to combine the right mix of resources, processes and technologies.

HX360 will provide a series of solutions and services to support health systems adoption of next generation technologies. This includes identifying key Contemporary Provider Challenges, which are areas of health care delivery identified in partnership with health systems that could immediately benefit from these new technologies. HX360 is also developing the HX360 Index, a new tool to help health system leaders calibrate their preparedness for tackling current challenges in health care delivery using new technologies. HX360 is partnering with related member organizations to serve as a content resource.

"Globally, health system leaders are looking to reinvent care delivery to not just treat illness, but manage the overall health of entire populations," said Dr. Roy Smythe, chief executive officer, HX360. "HX360 seeks to close the gaps that exist between the needs of health care leaders and the new technologies that have been created and will continue to evolve, or what we are referring to as next generation technologies."

"While platform technologies such as the electronic medical record have set the stage for improving health care delivery via more effective data collection, these technologies have also not substantially changed the way that clinical care is delivered. HX360 was created to help bring about meaningful change in clinical care delivery is using next generation technology" Smythe said.

In addition to the proprietary HX360 Index™ and identification of current Contemporary Provider Challenges, HX360 will offer exclusive, ongoing forums for health system executives to promote and test the actions and initiatives necessary to bring changes to health care delivery, including HX360's inaugural event, April 12-15, 2015 in Chicago.

More information about HX360 is available at www.hx360.org.

About HX360™

HX360 was created to improve the way that health care is delivered by both inspiring and facilitating the adoption and use of next generation (non-EHR Platform) technologies by provider organizations, in areas where health system executives are passionate to combine the right mix of resources, process and technology.

About HIMSS

HIMSS is a cause-based, global enterprise producing health IT thought leadership, education, events, market research and media services around the world. Founded in 1961, HIMSS encompasses more than 52,000 individuals, of which more than two-thirds work in healthcare provider, governmental and not-for-profit organizations across the globe, plus over 600 corporations and 250 not-for-profit partner organizations, that share this cause. HIMSS, headquartered in Chicago, serves the global health IT community with additional offices in the United States, Europe, and Asia.

About AVIA

AVIA is a provider-led innovation accelerator. AVIA addresses healthcare's most pressing challenges by working with provider organizations to identify and implement the best emerging tech-enabled solutions, at scale. AVIA's Innovator Network offers providers a higher probability of success and a quicker path to impact.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.